Cabenuva broke a pattern that had defined HIV treatment for decades, in which staying suppressed meant taking pills every single day. It is the first complete long-acting injectable regimen approved for HIV-1.
The regimen co-packages cabotegravir, an integrase strand transfer inhibitor, with rilpivirine, a non-nucleoside reverse transcriptase inhibitor, given as intramuscular injections once monthly or every two months. It is indicated for adults already virologically suppressed on a stable oral regimen.
Cabenuva has since anchored a broader shift toward long-acting HIV therapy and faces no generic competition. For competitive intelligence purposes it is the reference product for injectable maintenance regimens and a key comparator as other long-acting antiretrovirals advance.
